Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The detection of anti-p53 antibodies indicates that p53 is altered in amount, type or presentation in breast tumors so that it becomes immunogenic.
|
6292117 |
1982 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
We investigated the effects of the germ-line single nucleotide polymorphisms TP53 R72P (215G>C) and MDM2 SNP309 (-410T>G), and p53 protein expression in breast tumors on survival.
|
20021639 |
2009 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
A higher prevalence of p53 mutations was found in the breast tumors of current smokers (36.5%; P = 0.02) compared with never smokers (23.6%), whereas fewer mutations were found in former smokers (16.2%; P = 0.09).
|
11929815 |
2002 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
|
19147582 |
2009 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
This prognostic value may rely in part on the fact that p53 plays a role in the antiproliferative and apoptotic activities of chemotherapy regimens used to treat breast tumors.
|
20549698 |
2011 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The frequency of abnormalities affecting chromosome 17p and the TP53 gene was determined in 27 breast tumours from 26 female patients carrying the Icelandic BRCA2 founder mutation (999del5).
|
9467939 |
1998 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
In summary, a new sensitive and quantitative LIA suitable for routine analysis of p53 protein in steroid receptor cytosol preparations from breast tumours has been developed to confirm the prognostic importance of p53 protein accumulation in human breast cancer.
|
7734292 |
1995 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
We report here a rapid and robust induction of maspin expression in prostate cancer cells (LNCaP, DU145, and PC3) and breast tumor cells (MCF7) following wild type p53 expression from an adenovirus p53 expression vector (AdWTp53). p53 activates the maspin promoter by binding directly to the p53 consensus-binding site present in the maspin promoter.
|
10692390 |
2000 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
This work indicates that functional inactivation of the wild-type p53 protein and of the product of a gene located on 17q are essential to the development of breast neoplasms.
|
8137297 |
1994 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Our results in male breast tumors indicate a positive correlation between p53 mutation and p53 protein overexpression, whereas the results in female breast tumors indicate an overexpression of p53 protein even without p53 gene mutation.
|
8996549 |
1996 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
These protective effects of FR on survival and tumor incidence were paralleled by higher expression of the tumor suppressor gene p53 (wild type) and free-radical scavenging enzymes (catalase and superoxide dismutase) in breast tumors.
|
7604020 |
1995 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
This study aimed to objectively determine optimal thresholds for p53 positivity by manual and automated scoring methods using whole tissue sections from the Carolina Breast Cancer Study. p53-immunostained slides were available for 564 breast tumors previously assayed for TP53 mutations.
|
26200835 |
2016 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Furthermore, Notch-induced transcriptomes from p53 wild-type and -mutated breast tumor cell lines differed extensively, and for a subset of genes upregulated by Notch in a p53-mutant cell line, this upregulation was reduced by wild-type p53.
|
23178494 |
2013 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
The literature suggests that it is now appropriate to start assessing the p53 gene status of breast tumors for prognosis.
|
7664481 |
1995 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Here we describe the analysis of BRCA1, PTEN, and p53 at the single cell level in 55 BRCA1-associated breast tumors and computational methods to predict the relative temporal order of somatic events, on the basis of the frequency of cells with single or combined alterations.
|
22628410 |
2012 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Examination of all 49 breast tumors revealed a 61% frequency of deletion at or near the p53 locus.
|
2052583 |
1991 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
The tumour-suppressor gene TP53 is frequently mutated in breast tumours, and the majority of the mutations are clustered within the core domain, the region involved in DNA binding.
|
9569050 |
1998 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
Nuclear expression of CHEK1 was present in 61% of breast tumours and was associated with tumour size, triple-negative cancer, basal-like phenotype, the epithelial-mesenchymal transition, p53 over-expression, DNA homologous repair pathway dysfunction, and poor prognosis.
|
29075961 |
2018 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Mutations in the p53 tumor suppressor gene are frequent in breast tumors but the implication of p53 mutations in breast cancer development remains poorly understood.
|
15246568 |
2004 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
1-kb segment of the p53 tumor suppressor gene (54.5% G+C) containing exons 5-9, including the intervening introns, was screened in a blinded analysis of 48 samples from human breast tumors containing known wild-type or mutant p53 genes.
|
10425040 |
1999 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Household income is associated with the p53 mutation frequency in human breast tumors.
|
23469190 |
2013 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Expression of the ataxia telangiectasia (ATM) and p53 proteins was immunohistochemically evaluated in 18 benign and malignant myoepithelial tumours of the breast.
|
15509680 |
2004 |
Mammary Neoplasms
|
0.700 |
Biomarker
|
group |
BEFREE |
Our strategy involved using a retrovirus containing a p53-regulated lacZ reporter gene that was introduced into colon and breast tumor cell lines to determine p53 status.
|
12725531 |
2003 |
Mammary Neoplasms
|
0.700 |
AlteredExpression
|
group |
BEFREE |
There was an excellent correlation between the breast tumor cell lines and their corresponding tumor tissues for morphological features (100%); presence of aneuploidy (87%); immunohistochemical expression of estrogen receptors (87%), progesterone receptors (73%), and HER2/neu (93%) and p53 proteins (100%); allelic loss at all of the chromosomal regions analyzed (82-100% concordance); and TP53 gene mutations (75%).
|
9865903 |
1998 |
Mammary Neoplasms
|
0.700 |
GeneticVariation
|
group |
BEFREE |
Estrogen receptor negative (ER(-ve)) and p53 mutant breast tumors are highly aggressive and have fewer treatment options.
|
22027149 |
2011 |